ADC Therapeutics SA financials
$1.23−2.38%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $81.4M | $70.8M | $69.6M | $209.9M | $2.3M |
| Gross profit | $75.6M | $64.9M | $67.0M | $206.6M | $2.3M |
| Gross margin | 92.9% | 91.6% | 96.4% | 98.4% | 100.0% |
| Operating income | -$121.5M | -$130.7M | -$166.0M | -$123.3M | -$119.4M |
| Net income | -$142.6M | -$157.8M | -$240.1M | -$157.1M | -$116.5M |
| Net margin | −175.3% | −222.8% | −345.1% | −74.9% | −4977.9% |
| Diluted EPS | $-1.12 | $-1.62 | $-2.94 | $-2.01 | $-2.64 |
| EBITDA | -$107.7M | -$129.3M | -$164.8M | -$121.0M | -$117.8M |
| Operating cash flow | -$141.2M | -$123.8M | -$118.7M | -$138.3M | -$121.6M |
| Free cash flow | -$141.4M | -$124.7M | -$121.9M | -$139.0M | -$121.9M |
| Diluted shares | 127.1M | 97.2M | 81.7M | 78.2M | 44.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $261.3M | $250.9M | $278.6M | $326.4M | $115.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $115.5M | $113.6M | $112.7M | $322.1M | $0.00 |
| Total assets | $323.1M | $322.0M | $354.8M | $490.9M | $137.7M |
| Total liabilities | $509.0M | $524.6M | $503.0M | $411.4M | $26.5M |
| Shareholders' equity | -$185.8M | -$202.6M | -$148.2M | $79.5M | $111.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology